VivoSeq
Other

Complete Response

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Complete Response is an early-stage landscape with 0 programs across 4 companies. The most active players are Novartis, Zydus Therapeutics Inc., Kyowa Kirin Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalZ

Zydus Therapeutics Inc.

0 programs

PreclinicalKyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

0 programs

PreclinicalFerring logo

Ferring

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed9 · 56%
Unknown status2 · 13%
Recruiting2 · 13%
Active, not recruiting1 · 6%
Not yet recruiting1 · 6%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

16 trials

Clinical Research of Tapering UDCA in PBC Patients With a Complete Response
Recruiting·PPeking Union Medical College Hospital·Phase 4·NCT04650243·90 enrolled
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
Recruiting·WWake Forest University Health Sciences·Phase 2·NCT04677816·50 enrolled
TNT to Increase the Clinical Complete Response Rate for Distal LARC
Active, not recruiting·SSun Yat-sen University·Phase 2·NCT03840239·98 enrolled
Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy
Not yet recruiting·ZZydus Therapeutics Inc.·Phase 3·NCT07424677·89 enrolled
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
Completed·Novartis logoNovartis·Phase 1·NCT00441155·14 enrolled
AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment
Completed·MMclean Hospital·Phase 4·NCT00304746·100 enrolled
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Completed·Kyowa Kirin Co., Ltd. logoKyowa Kirin Co., Ltd.·Phase 2·NCT01226472·1 enrolled
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
Completed·—·Phase 2·NCT02176291·31 enrolled
Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy
Completed·RRush University Medical Center·Phase 4·NCT02058693·41 enrolled
Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)
Completed·UUniversity of Pittsburgh·Phase 4·NCT00892047·468 enrolled
PEG-IFN in HBV Patients With Incomplete Response to NA
Completed·FFoundation for Liver Research·Phase 4·NCT00883844·11 enrolled
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
Completed·CCentre for Addiction and Mental Health·Phase 1/2·NCT02263248·56 enrolled
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)
Completed·UUniversity Health Network, Toronto·Phase 2·NCT02543255·76 enrolled
A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
Withdrawn·Ferring logoFerring·Phase 4·NCT06390111
Tailored Sonidegib Schedule After Complete Response in BCC
Unknown status·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT04806646·21 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)